Recombinant human insulin-like growth factor-I (IGF-I) therapy decreases plasma leptin concentration in patients with chronic renal insufficiency

Samuel Dagogo-Jack, S. C. Franklin, A. Vijayan, J. Liu, H. Askari, S. B. Miller

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

OBJECTIVE: To determine the relationship between plasma leptin and insulin-like growth factor-I (IGF-I) levels in healthy subjects and patients with chronic renal insufficiency at baseline, and during administration of recombinant human IGF-I in the renal impaired patients. SUBJECTS: 20 healthy subjects (six men, 14 women, age: 42.7 ± 3.2 y) and nine subjects with chronic renal insufficiency (five men, four women, age: 53.6 ± 3.7 y). INTERVENTION: Daily sc injection of recombinant human IGF-I (50 μg/kg) for 24 d. MEASUREMEMTS: Fasting plasma levels of leptin, IGF-I, growth hormone, C-peptide, glucagon and IGF binding proteins by specific radioimmunoassays at baseline in all subjects and serially during IGF-I therapy in the renal impaired subjects. RESULTS: Baseline leptin levels were correlated with body mass index (BMI, R = 0.72, P = 0.0001) but not IGF-I levels (R = 0.02). During IGF-I therapy, plasma IGF-I levels increased from 128 ± 17.4 ng/ml at baseline to 250 ± 36.8 ng/ml on day 3 (P = 0.003) and 323 ± 61.6 ng/ml on day 24 (P = 0.01), whereas leptin levels declined: 24.4 ± 10.3 ng/ml (baseline), 19.5 ± 6.2 ng/ml (day 3, P = 0.028), and 17.2 ± 4.9 ng/ml (day 24, P = 0.05). CONCLUSION: Basal plasma leptin and IGF-I levels are not correlated; however, chronic administration of recombinant IGF-I is associated with an early and sustained decrease in plasma leptin levels. IGF-I may have an inhibitory effect on leptin secretion in humans.

Original languageEnglish (US)
Pages (from-to)1110-1115
Number of pages6
JournalInternational Journal of Obesity
Volume22
Issue number11
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Leptin
Insulin-Like Growth Factor I
Chronic Renal Insufficiency
Therapeutics
Healthy Volunteers
Kidney
Insulin-Like Growth Factor Binding Proteins
C-Peptide
Glucagon
Growth Hormone
Radioimmunoassay
Fasting
Body Mass Index
Injections

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Recombinant human insulin-like growth factor-I (IGF-I) therapy decreases plasma leptin concentration in patients with chronic renal insufficiency. / Dagogo-Jack, Samuel; Franklin, S. C.; Vijayan, A.; Liu, J.; Askari, H.; Miller, S. B.

In: International Journal of Obesity, Vol. 22, No. 11, 01.01.1998, p. 1110-1115.

Research output: Contribution to journalArticle

@article{9c7a777e4cf94bb9960989f90c5c6999,
title = "Recombinant human insulin-like growth factor-I (IGF-I) therapy decreases plasma leptin concentration in patients with chronic renal insufficiency",
abstract = "OBJECTIVE: To determine the relationship between plasma leptin and insulin-like growth factor-I (IGF-I) levels in healthy subjects and patients with chronic renal insufficiency at baseline, and during administration of recombinant human IGF-I in the renal impaired patients. SUBJECTS: 20 healthy subjects (six men, 14 women, age: 42.7 ± 3.2 y) and nine subjects with chronic renal insufficiency (five men, four women, age: 53.6 ± 3.7 y). INTERVENTION: Daily sc injection of recombinant human IGF-I (50 μg/kg) for 24 d. MEASUREMEMTS: Fasting plasma levels of leptin, IGF-I, growth hormone, C-peptide, glucagon and IGF binding proteins by specific radioimmunoassays at baseline in all subjects and serially during IGF-I therapy in the renal impaired subjects. RESULTS: Baseline leptin levels were correlated with body mass index (BMI, R = 0.72, P = 0.0001) but not IGF-I levels (R = 0.02). During IGF-I therapy, plasma IGF-I levels increased from 128 ± 17.4 ng/ml at baseline to 250 ± 36.8 ng/ml on day 3 (P = 0.003) and 323 ± 61.6 ng/ml on day 24 (P = 0.01), whereas leptin levels declined: 24.4 ± 10.3 ng/ml (baseline), 19.5 ± 6.2 ng/ml (day 3, P = 0.028), and 17.2 ± 4.9 ng/ml (day 24, P = 0.05). CONCLUSION: Basal plasma leptin and IGF-I levels are not correlated; however, chronic administration of recombinant IGF-I is associated with an early and sustained decrease in plasma leptin levels. IGF-I may have an inhibitory effect on leptin secretion in humans.",
author = "Samuel Dagogo-Jack and Franklin, {S. C.} and A. Vijayan and J. Liu and H. Askari and Miller, {S. B.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1038/sj.ijo.0800735",
language = "English (US)",
volume = "22",
pages = "1110--1115",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Recombinant human insulin-like growth factor-I (IGF-I) therapy decreases plasma leptin concentration in patients with chronic renal insufficiency

AU - Dagogo-Jack, Samuel

AU - Franklin, S. C.

AU - Vijayan, A.

AU - Liu, J.

AU - Askari, H.

AU - Miller, S. B.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - OBJECTIVE: To determine the relationship between plasma leptin and insulin-like growth factor-I (IGF-I) levels in healthy subjects and patients with chronic renal insufficiency at baseline, and during administration of recombinant human IGF-I in the renal impaired patients. SUBJECTS: 20 healthy subjects (six men, 14 women, age: 42.7 ± 3.2 y) and nine subjects with chronic renal insufficiency (five men, four women, age: 53.6 ± 3.7 y). INTERVENTION: Daily sc injection of recombinant human IGF-I (50 μg/kg) for 24 d. MEASUREMEMTS: Fasting plasma levels of leptin, IGF-I, growth hormone, C-peptide, glucagon and IGF binding proteins by specific radioimmunoassays at baseline in all subjects and serially during IGF-I therapy in the renal impaired subjects. RESULTS: Baseline leptin levels were correlated with body mass index (BMI, R = 0.72, P = 0.0001) but not IGF-I levels (R = 0.02). During IGF-I therapy, plasma IGF-I levels increased from 128 ± 17.4 ng/ml at baseline to 250 ± 36.8 ng/ml on day 3 (P = 0.003) and 323 ± 61.6 ng/ml on day 24 (P = 0.01), whereas leptin levels declined: 24.4 ± 10.3 ng/ml (baseline), 19.5 ± 6.2 ng/ml (day 3, P = 0.028), and 17.2 ± 4.9 ng/ml (day 24, P = 0.05). CONCLUSION: Basal plasma leptin and IGF-I levels are not correlated; however, chronic administration of recombinant IGF-I is associated with an early and sustained decrease in plasma leptin levels. IGF-I may have an inhibitory effect on leptin secretion in humans.

AB - OBJECTIVE: To determine the relationship between plasma leptin and insulin-like growth factor-I (IGF-I) levels in healthy subjects and patients with chronic renal insufficiency at baseline, and during administration of recombinant human IGF-I in the renal impaired patients. SUBJECTS: 20 healthy subjects (six men, 14 women, age: 42.7 ± 3.2 y) and nine subjects with chronic renal insufficiency (five men, four women, age: 53.6 ± 3.7 y). INTERVENTION: Daily sc injection of recombinant human IGF-I (50 μg/kg) for 24 d. MEASUREMEMTS: Fasting plasma levels of leptin, IGF-I, growth hormone, C-peptide, glucagon and IGF binding proteins by specific radioimmunoassays at baseline in all subjects and serially during IGF-I therapy in the renal impaired subjects. RESULTS: Baseline leptin levels were correlated with body mass index (BMI, R = 0.72, P = 0.0001) but not IGF-I levels (R = 0.02). During IGF-I therapy, plasma IGF-I levels increased from 128 ± 17.4 ng/ml at baseline to 250 ± 36.8 ng/ml on day 3 (P = 0.003) and 323 ± 61.6 ng/ml on day 24 (P = 0.01), whereas leptin levels declined: 24.4 ± 10.3 ng/ml (baseline), 19.5 ± 6.2 ng/ml (day 3, P = 0.028), and 17.2 ± 4.9 ng/ml (day 24, P = 0.05). CONCLUSION: Basal plasma leptin and IGF-I levels are not correlated; however, chronic administration of recombinant IGF-I is associated with an early and sustained decrease in plasma leptin levels. IGF-I may have an inhibitory effect on leptin secretion in humans.

UR - http://www.scopus.com/inward/record.url?scp=0031734138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031734138&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0800735

DO - 10.1038/sj.ijo.0800735

M3 - Article

VL - 22

SP - 1110

EP - 1115

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 11

ER -